Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 May 6:9:F1000 Faculty Rev-336.
doi: 10.12688/f1000research.19444.1. eCollection 2020.

Exome sequencing in genetic disease: recent advances and considerations

Affiliations
Review

Exome sequencing in genetic disease: recent advances and considerations

Jay P Ross et al. F1000Res. .

Abstract

Over the past decade, exome sequencing (ES) has allowed significant advancements to the field of disease research. By targeting the protein-coding regions of the genome, ES combines the depth of knowledge on protein-altering variants with high-throughput data generation and ease of analysis. New discoveries continue to be made using ES, and medical science has benefitted both theoretically and clinically from its continued use. In this review, we describe recent advances and successes of ES in disease research. Through selected examples of recent publications, we explore how ES continues to be a valuable tool to find variants that might explain disease etiology or provide insight into the biology underlying the disease. We then discuss shortcomings of ES in terms of variant discoveries made by other sequencing technologies that would be missed because of the scope and techniques of ES. We conclude with a brief outlook on the future of ES, suggesting that although newer and more thorough sequencing methods will soon supplant ES, its results will continue to be useful for disease research.

Keywords: disease research; whole exome sequencing; whole genome sequencing.

PubMed Disclaimer

Conflict of interest statement

No competing interests were disclosed.No competing interests were disclosed.No competing interests were disclosed.

Similar articles

Cited by

References

    1. Elborn JS: Cystic fibrosis. Lancet. 2016;388(10059):2519–31. 10.1016/S0140-6736(16)00576-6 - DOI - PubMed
    1. Walker FO: Huntington's disease. Lancet. 2007;369(9557):218–28. 10.1016/S0140-6736(07)60111-1 - DOI - PubMed
    1. Peltonen L, Perola M, Naukkarinen J, et al. : Lessons from studying monogenic disease for common disease. Hum Mol Genet. 2006;15 Spec No 1:R67–74. 10.1093/hmg/ddl060 - DOI - PubMed
    1. Petersen BS, Fredrich B, Hoeppner MP, et al. : Opportunities and challenges of whole-genome and -exome sequencing. BMC Genet. 2017;18(1):14. 10.1186/s12863-017-0479-5 - DOI - PMC - PubMed
    1. Botstein D, Risch N: Discovering genotypes underlying human phenotypes: Past successes for mendelian disease, future approaches for complex disease. Nat Genet. 2003;33 Suppl:228–37. 10.1038/ng1090 - DOI - PubMed

Publication types

Grants and funding